PVLA
Palvella Therapeutics, Inc
131.30$
+0.6%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | – | – | – | – | – | – | – | – | – | |
| 7.5% | 6.1% | 1.4% | – | 3.2% | 1.2% | 1.6% | – | – | – | – | – | – | – | – | – | – | – | – | 7.0% | 7.6% | 15.5% | 14.4% | 10.0% | 29.5% | 3.6% | 3.8% | – | -56.6% | – | – | – | – | – | – | – | – | – | – | |
| 92.6% | 93.9% | 98.6% | – | 96.8% | 98.8% | 98.4% | – | – | – | – | – | – | – | – | – | – | – | – | 93.0% | 92.4% | 84.5% | 85.6% | 90.0% | 70.5% | 96.4% | 96.2% | 100.0% | – | – | – | – | – | – | – | – | – | – | – | |
| 391.7% | 285.1% | 158.0% | 28.5% | 187.9% | 77.1% | 135.1% | 261.2% | 167.3% | 250.8% | 87.3% | 80.2% | 93.7% | 96.1% | 376.6% | 529.0% | 101.9% | 462.2% | 451.8% | 174.7% | 120.3% | 307.3% | 238.8% | 219.0% | 662.1% | 67.7% | 49.2% | 342.9% | 1,856.6% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 47.7% | – | – | – | 1,462.3% | – | – | – | – | – | – | – | – | – | – | |
| 688.6% | 519.8% | 230.6% | 63.7% | 292.7% | 118.0% | 192.0% | 354.0% | 223.1% | 328.6% | 118.2% | 103.8% | 125.0% | 136.7% | 525.5% | 728.9% | 128.5% | 592.1% | 554.2% | 223.3% | 160.2% | 417.9% | 312.2% | 287.0% | 871.7% | 86.1% | 80.4% | 522.0% | 3,318.9% | – | – | – | – | – | – | – | – | – | – | |
| -596.1% | -425.8% | -132.0% | 35.7% | -196.0% | -19.2% | -93.5% | -257.4% | -125.0% | -229.4% | -19.3% | -7.7% | -29.1% | -41.4% | -442.3% | -661.2% | -32.4% | -510.2% | -468.6% | -130.3% | -67.9% | -333.4% | -226.6% | -197.0% | -801.2% | 10.3% | 15.8% | -422.0% | -3,318.9% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.1% | 0.0% | – | – | – | 133.2% | – | – | – | 1,518.9% | – | – | – | – | – | – | – | – | – | – | |
| -595.2% | -500.3% | -176.0% | 42.1% | -209.9% | -3.0% | -73.7% | -241.1% | -121.1% | -220.5% | -17.1% | -4.5% | -27.1% | -44.0% | -486.0% | -758.4% | -26.7% | -471.8% | -407.6% | -112.9% | -46.4% | -279.6% | -181.3% | -138.6% | -680.9% | 19.8% | -55.1% | -352.9% | -4,784.9% | – | – | – | – | – | – | – | – | – | – | |
| – | 43.9% | 3.7% | 0.8% | – | -1.3% | – | -3.3% | – | – | – | – | – | – | – | 8.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -595.2% | -544.3% | -179.8% | 41.3% | -209.9% | -1.7% | -73.7% | -237.7% | -121.1% | -220.5% | -17.1% | -4.5% | -27.1% | -44.0% | -486.0% | -767.2% | -26.7% | -471.8% | -407.6% | -112.9% | -46.4% | -279.6% | -181.3% | -138.6% | -680.9% | 19.8% | -55.1% | -352.9% | -4,784.9% | – | – | – | – | – | – | – | – | – | – | |
| -587.7% | -494.2% | -174.6% | 42.6% | -206.6% | -1.8% | -72.2% | -237.7% | -119.2% | -219.7% | -16.1% | -0.6% | -23.1% | -39.3% | -469.1% | -726.1% | -22.8% | -453.7% | -393.1% | -105.9% | -38.8% | -264.1% | -166.9% | -128.6% | -651.4% | 23.4% | -51.3% | -352.9% | -3,266.0% | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.